Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action

…, JC Drach, LB Townsend, GW Koszalka - Antimicrobial agents …, 2002 - Am Soc Microbiol
Koszalka. June 2000. Antiviral benzimidazole nucleoside analogues and a method for their
Koszalka. 1999. Development of novel benzimdazole riboside compounds for treatment of …

Design, Synthesis, and Antiviral Activity of α-Nucleosides:  d- and l-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles

…, JL Girardet, JA Walker, GW Koszalka… - Journal of Medicinal …, 1998 - ACS Publications
Several 2-substituted α-d- and α-l-lyxofuranosyl and 5-deoxylyxofuranosyl derivatives of 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)benzimidazole
(1263W94) and 2,5,6-…

Purine nucleoside synthesis: an efficient method employing nucleoside phosphorylases

TA Krenitsky, GW Koszalka, JV Tuttle - Biochemistry, 1981 - ACS Publications
Thomas A. Krenitsky,* George W. Koszalka, and Joel V. Tuttle abstract: An improved method
for the enzymatic synthesis of purine nucleosides is described. Pyrimidine nucleosides …

[HTML][HTML] The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology

C Mao, WJ Cook, M Zhou, GW Koszalka, TA Krenitsky… - Structure, 1997 - cell.com
Background: Purine nucleoside phosphorylase (PNP) from Escherichia coli is a hexameric
enzyme that catalyzes the reversible phosphorolysis of 6-amino and 6-oxopurine (2′-deoxy)…

Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution.

…, WJ Cook, LB Cole, SA Short, GW Koszalka… - Journal of Biological …, 1990 - ASBMB
The three-dimensional structure of thymidine phosphorylase from Escherichia coli has been
determined at 2.8 A resolution using multiple-isomorphous-replacement techniques. The …

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

GW Koszalka, NW Johnson, SS Good… - Antimicrobial agents …, 2002 - Am Soc Microbiol
… Ferris, RE Dornsife, SC Stanat, JC Drach, LB Townsend, and GW Koszalka. 2002. Potent and
Koszalka. 1999. Development of novel benzimdazole riboside compounds for treatment of …

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.

…, JR Cowan, SS Gonzales, GW Koszalka… - Journal of medicinal …, 2004 - ACS Publications
HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination
therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV …

Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2', 3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds

…, LE Strange, DC Liotta, GW Koszalka… - The Journal of …, 1992 - ACS Publications
Racemic 2', 3'-dideoxy-3/-thianucleosides were resolved by enzyme-catalyzed hydrolysis of
their butyrate ester derivatives. Recently, we required the enantiomers of the important …

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1

…, SA Short, K Weaver, GW Koszalka… - Journal of medicinal …, 2004 - ACS Publications
GW4511, GW4751, and GW3011 showed IC 50 values ≤2 nM against wild type HIV-1 and
<10 nM against 16 mutants. They were particularly potent against NNRTI-resistant viruses …

Imidazo [4, 5-c] pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents

…, JL Rideout, EY Chao, GW Koszalka… - Journal of medicinal …, 1986 - ACS Publications
A variety of imidazo [4, 5-c] pyridines (3-deazapurines) were synthesized. With use of these
aglycons as pentosyl acceptors, the corresponding ribonucleosides and 2'-…